A recent European survey has found major discrepancies and gaps in hospital policies and procedures to prevent the direct transmission of hepatitis B virus (HBV) from mother to child, particularly before and after birth.
In obese patients without gallstones, a 6-month treatment course of ursodeoxycholic acid (UDCA) following bariatric surgery may reduce their likelihood of developing symptomatic gallstones, according to findings of the UPGRADE trial from The Netherlands presented at DDW 2021.
Children whose mothers had taken fish oil supplements during the second half of pregnancy appeared to have better problem-solving skills and attention focus at age 10 vs those whose mothers had consumed folic acid alone or no supplements at all in a study presented at WCPGHAN 2021.
The recurrent waves of the COVID-19 pandemic are having a significant impact on healthcare workers, and Medical Protection has called for more to be done globally to ensure that medical professionals have quick access to mental wellbeing support.
A Singapore study suggests that doctors who want to predict postoperative mortality in hepatocellular carcinoma (HCC) patients after hepatic resection should look at the following: intraoperative blood loss, Child-Pugh score, posthepatectomy liver failure (PLHF), and peak serum bilirubin.
The combination of the immune checkpoint inhibitor atezolizumab and the angiogenesis inhibitor bevacizumab continues to demonstrate significant clinical benefits vs the oral multikinase inhibitor sorafenib in patients with unresectable hepatocellular carcinoma (HCC), according to updated results from the IMbrave150 trial.
Ascitic drain removal (ADR) within 24 hours among cirrhosis patients with refractory ascites appears to lower the risk of ascitic drain-related bacterial peritonitis (AdBP) and acute kidney injury (AKI), according to a Singapore study.
Weekly (QW) or biweekly (Q2W) treatment with BIO89-100 led to a significantly reduced liver fat and liver fat volume (LFV) in patients with nonalcoholic steatohepatitis (NASH), according to a recent study presented at ENDO 2021.
New drug applications approved by US FDA as of 16-31 March 2021 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.